List of Excipients in Branded Drug INBRIJA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merz Pharmaceuticals LLC	INBRIJA	levodopa	0259-6142	DIPALMITOYLPHOSPHATIDYLCHOLINE, DL-	2032-11-16
Merz Pharmaceuticals LLC	INBRIJA	levodopa	0259-6142	SODIUM CHLORIDE	2032-11-16
Merz Pharmaceuticals LLC	INBRIJA	levodopa	10144-342	DIPALMITOYLPHOSPHATIDYLCHOLINE, DL-	2032-11-16
Merz Pharmaceuticals LLC	INBRIJA	levodopa	10144-342	SODIUM CHLORIDE	2032-11-16

Inbrija Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Inbrija is a carrier-free inhaled levodopa product whose commercial differentiation depends on particle engineering, pulmonary deposition, phospholipid selection, capsule performance, and proprietary inhaler design. The principal excipient is dipalmitoylphosphatidylcholine, or DPPC, a lung-surfactant phospholipid used to improve aerosol performance and pulmonary tolerability. The strongest commercial opportunities are inhalation-grade phospholipid supply, spray-dried particle manufacturing, device-compatible capsule systems, generic development, and reformulations that improve dose consistency or reduce dependence on the current inhaler.

What is Inbrija and how does its excipient system work?

Inbrija contains levodopa inhalation powder for intermittent treatment of off episodes in adults with Parkinson's disease receiving carbidopa/levodopa therapy. It is approved as a 42 mg capsule administered through the Inbrija inhaler, with a recommended dose of two capsules per off episode and a maximum of five doses per day.[1]

The formulation uses spray-dried levodopa particles containing DPPC. The product is designed for pulmonary delivery rather than gastrointestinal absorption. The formulation objective is to produce particles that:

• Reach the lower respiratory tract;
• Disperse from the capsule and inhaler;
• Avoid excessive aggregation;
• Dissolve rapidly in lung fluid;
• Deliver a clinically meaningful levodopa dose within minutes.

The excipient strategy is therefore inseparable from the device. Inbrija is not a conventional dry-powder blend in which levodopa is mixed with lactose or another carrier. The active pharmaceutical ingredient and phospholipid are engineered into inhalable particles, and the inhaler controls deaggregation and emitted dose.

What excipients are used in Inbrija?

The FDA prescribing information identifies levodopa as the active ingredient and DPPC as the inactive ingredient in the inhalation powder.[1] DPPC is also known as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine.

Component	Function	Commercial relevance
Levodopa	Active pharmaceutical ingredient	High-dose, poorly water-soluble molecule requiring particle engineering
DPPC	Pulmonary phospholipid excipient	Supports dispersibility, aerosolization and lung compatibility
Capsule shell	Dose container	Controls powder protection, puncture behavior and device compatibility
Inhaler components	Delivery system	Determines emitted dose, capsule emptying and patient usability

The absence of a conventional lactose carrier creates both advantages and barriers. A carrier-free system can limit excipient mass and support rapid dissolution, but it places greater technical pressure on spray drying, particle morphology, electrostatic behavior, moisture control and inhaler design.

Why is DPPC strategically important for Inbrija?

DPPC is strategically important because it can perform several functions at the same time. It is a lung-compatible phospholipid, a particle-engineering aid and an aerosol-performance component.

Pulmonary compatibility

DPPC is a major constituent of endogenous pulmonary surfactant. That profile makes it attractive for inhaled delivery, although supplier quality, impurities, oxidation, residual solvents and microbiological control remain critical. Pharmaceutical-grade DPPC is not interchangeable with material used in nutritional, cosmetic or research applications.

Aerosol performance

In a spray-dried particle, DPPC can influence:

• Particle density;
• Surface composition;
• Cohesion;
• Moisture uptake;
• Powder dispersibility;
• Fine-particle fraction;
• Delivered-dose uniformity.

The commercial target is not the smallest possible particle. Particles generally must balance aerodynamic size with physical stability and efficient dispersion. Excessively small or low-density particles may be difficult to handle, may become electrostatically cohesive or may be exhaled rather than deposited.

Rapid dissolution

The pulmonary route can produce faster levodopa exposure than oral administration during an off episode. A formulation that improves wetting and dissolution without increasing local irritation has commercial value. DPPC selection, particle porosity, residual moisture and crystallinity can all affect this performance.

Supply-chain risk

DPPC is a specialized excipient relative to standard oral-product materials. Supply contracts should address:

• Synthetic or semisynthetic source;
• Fatty-acid chain distribution;
• Phospholipid purity;
• Oxidation products;
• Peroxide and acid values;
• Residual solvents;
• Elemental impurities;
• Sterility or bioburden controls;
• Lot-to-lot aerosol performance;
• Change-control requirements.

A second-source DPPC supplier may require formulation bridging, comparability testing and regulatory variation management. A supplier that can provide qualified pharmaceutical-grade material with stable aerosol performance can capture value beyond the raw-material margin.

What excipient and formulation patents protect Inbrija?

Inbrija's protection is likely concentrated in the combination of formulation, particle manufacturing, pulmonary delivery and inhaler-device claims rather than in levodopa itself. Levodopa is an old molecule and does not provide meaningful composition-of-matter exclusivity.

The relevant patent layers are:

Patent layer	Protected subject matter	Competitive impact
Formulation composition	Levodopa particles containing phospholipid excipient	Can limit direct formulation replication
Particle engineering	Spray-dried morphology, density, size and surface properties	Raises development and bioequivalence barriers
Manufacturing process	Conditions used to produce the inhalation powder	Can restrict non-infringing process options
Delivery device	Inhaler geometry, airflow and capsule puncture	May require a different device for generic entry
Method of use	Pulmonary levodopa treatment of off episodes	May remain relevant after composition claims expire
Capsule and packaging	Dose presentation and moisture protection	Usually a secondary barrier but relevant to substitutability

The FDA Orange Book is the controlling public source for patents listed against the U.S. NDA, including patent numbers and reported expiration dates.[2] A commercial diligence review should separate listed patents into three categories:

1. Patents that cover the formulation itself;
2. Patents that cover the inhaler or capsule system;
3. Method-of-use patents that may be narrower or more difficult to enforce against an approved label.

Patent strength depends on claim scope, prosecution history, written-description support, enablement, terminal disclaimers, PTA or PTE adjustments, and whether an alternative DPPC-containing or DPPC-free particle system can avoid the claims.

When does Inbrija lose exclusivity?

Inbrija's regulatory and patent exclusivity must be analyzed separately.

Exclusivity category	Relevance to Inbrija
New chemical entity exclusivity	Not available because levodopa is an established active ingredient
New formulation or new drug application exclusivity	May apply based on the approved inhaled product and FDA designation
Orphan-drug exclusivity	Parkinson's disease is not generally an orphan indication for Inbrija
Listed patents	May delay an ANDA applicant depending on patent scope and litigation
Regulatory exclusivity	Controls the timing of certain generic filings and approvals
Device-related protection	May influence commercial substitution even after approval

Inbrija was approved by the FDA in December 2018.[3] Its commercial exclusivity is therefore driven primarily by formulation, device, process and method-of-use patents rather than by a new chemical entity patent.

A generic applicant would likely need to pursue an abbreviated new drug application, or ANDA, if it can demonstrate pharmaceutical equivalence and bioequivalence. The product-specific requirements may be demanding because the reference product has an inhalation device, a carrier-free powder and a locally acting pulmonary delivery route. FDA may require comparative aerodynamic particle-size distribution, delivered-dose uniformity, emitted dose, fine-particle dose, device performance and pharmacokinetic data.[4]

Exact patent expiration analysis should use the current Orange Book listing, patent term adjustment records and litigation docket. The relevant commercial date is the earliest date on which a legally approvable and technically substitutable generic can launch, not simply the earliest nominal patent expiration.

What generic entry risks exist for Inbrija?

Generic entry risk is moderate to high over the long term but technically more complex than for an oral levodopa tablet.

Paragraph IV challenges

An ANDA applicant may file a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable or not infringed. The filing can trigger patent litigation under the Hatch-Waxman Act and a potential 30-month stay of approval under the statutory framework.[5]

The most vulnerable patents may be:

• Narrow method-of-use claims;
• Claims limited to specific dose ranges;
• Claims with vulnerable written-description support;
• Device claims that can be avoided with a redesigned inhaler;
• Process claims that do not cover independently developed manufacturing routes.

The strongest barriers may be claims covering the particle composition itself, particularly where the claims combine levodopa, DPPC, aerodynamic properties and performance parameters.

Bioequivalence and device risk

A generic company must match more than the nominal 42 mg capsule strength. It must reproduce the relevant delivery profile. Key development variables include:

• Capsule rupture and emptying;
• Powder deaggregation;
• Inhaler resistance;
• Inspiratory-flow sensitivity;
• Fine-particle dose;
• Regional lung deposition;
• Delivered-dose uniformity;
• Levodopa dissolution;
• Systemic pharmacokinetic exposure.

A product can contain the same active ingredient and still fail to demonstrate equivalence if it produces a different aerodynamic distribution or dose-emission profile.

Substitution risk

Automatic pharmacy substitution may be limited if the generic uses a different device or if FDA assigns different therapeutic-equivalence conditions. A product that requires a new inhaler training routine could face slower uptake even after approval.

What commercial opportunities exist in Inbrija excipients?

Pharmaceutical-grade DPPC supply

The most direct opportunity is qualified DPPC supply. A supplier can compete on:

• High chemical purity;
• Low oxidation;
• Controlled particle morphology;
• Consistent spray-drying behavior;
• Regulatory documentation;
• Dual manufacturing sites;
• Long-term stability;
• Scale-up support.

The supplier's value increases if it provides formulation-development lots, analytical methods and change-control packages rather than only bulk DPPC.

Custom spray drying

Contract development and manufacturing organizations can offer inhalation-specific spray drying for levodopa and other poorly soluble molecules. Required capabilities include:

• Closed-system spray drying;
• Low-temperature processing;
• Control of residual moisture;
• Particle-size engineering;
• Inhalation-grade containment;
• Powder handling at low bulk density;
• Nonclinical inhalation testing;
• Cascade impaction and aerodynamic characterization.

The process may be more commercially defensible than the excipient itself because particle morphology and performance are difficult to reproduce from a public formulation description.

Inhaler and capsule manufacturing

A device supplier can pursue opportunities in:

• Single-dose dry-powder inhalers;
• Low-resistance devices for Parkinson's patients;
• Capsule puncture mechanisms;
• Dose counters;
• Priming-free inhalers;
• Human-factors engineering;
• Child-resistant packaging;
• Moisture-barrier blister systems.

The commercial objective is to improve ease of use without changing the reference-product performance profile.

Lifecycle reformulation

Potential lifecycle strategies include:

Strategy	Potential benefit	Development barrier
Higher-strength capsule	Fewer capsules per off episode	Dose proportionality and safety
Improved inhaler	More consistent emitted dose	Device comparability
Alternative phospholipid	Supply security or better stability	New formulation and toxicology work
DPPC-free formulation	Freedom to operate	May lose aerosol or tolerability advantages
Moisture-resistant packaging	Longer shelf life	Package qualification
Breath-actuated system	Easier patient use	Device development and human factors
Combination rescue therapy	Broader off-episode management	New clinical and regulatory program

A reformulation using a different phospholipid may create a new patent position, but it would also create regulatory comparability risk. DPPC remains attractive because its pulmonary-surfactant profile is familiar and its technical role is established.

How does Inbrija compare with competing Parkinson's rescue products?

Inbrija competes with oral and non-oral treatments for off episodes, including apomorphine injection, sublingual apomorphine and inhaled or other rapid-acting levodopa approaches.

Product category	Active ingredient	Administration	Excipient and device implication
Inbrija	Levodopa	Inhaled powder	Carrier-free spray-dried particles and dedicated inhaler
Oral levodopa formulations	Levodopa with decarboxylase inhibitor	Tablet or capsule	Conventional excipient systems, slower onset
Apomorphine injection	Apomorphine	Subcutaneous injection	Sterile liquid formulation and injection device
Sublingual apomorphine	Apomorphine	Sublingual film or tablet	Mucoadhesive or rapidly dissolving dosage form
Future pulmonary levodopa products	Levodopa	Inhaled powder or aerosol	Potentially competing phospholipid and particle platforms

Inbrija's technical advantage is rapid pulmonary delivery without an injection. Its disadvantages include dependence on inhaler technique, capsule handling, coughing or throat irritation concerns, and the need to carry a dedicated device.

What FDA regulatory issues affect Inbrija excipient development?

FDA's regulatory focus for an inhaled excipient system includes local pulmonary safety, impurity control and consistent aerosol performance. DPPC is familiar as a pulmonary-surfactant-related material, but each supplier and manufacturing process must be qualified for the intended route and dose.

Critical controls include:

• Excipient identity and purity;
• Oxidative degradation;
• Residual solvent profile;
• Microbial quality;
• Particle-size distribution;
• Morphology and density;
• Delivered-dose uniformity;
• Aerodynamic particle-size distribution;
• Dissolution in simulated lung fluid;
• Stability under humidity stress;
• Device-excipient interaction.

Inhaled products also require tight control of extractables and leachables from capsules, inhaler components, blister materials and packaging. A change from one DPPC source to another can affect both chemistry and aerosol performance, making supplier changes potentially more significant than for an oral tablet.

How strong is the Inbrija patent estate?

The estate is strongest where formulation, particle properties and device performance are claimed together. It is weaker where protection depends only on levodopa's use for Parkinson's disease or on a narrow administration instruction.

Strength factors

• Levodopa is delivered through a differentiated pulmonary route;
• DPPC and particle-engineering claims may create formulation barriers;
• The inhaler is integrated with the capsule presentation;
• Generic developers must match both product and delivery system;
• Manufacturing know-how may not be fully visible in issued claims.

Weakness factors

• Levodopa is an old active ingredient;
• Alternative dry-powder inhaler designs may avoid device claims;
• Non-infringing spray-drying processes may be available;
• Method-of-use claims can be narrow;
• Regulatory approval does not prevent a technically adequate competing product after enforceable claims expire.

The practical defense is therefore a layered estate supported by trade secrets covering spray-drying parameters, powder handling, in-process controls and device assembly.

Which companies can capture commercial value from Inbrija?

Commercial opportunities extend beyond the marketing authorization holder.

Opportunity	Potential beneficiary
DPPC manufacture	Specialty phospholipid suppliers
Spray-dried levodopa	Inhalation CDMOs
Capsule production	Pharmaceutical capsule manufacturers
Inhaler production	Dry-powder inhaler developers
Analytical testing	CROs with inhalation laboratories
Generic development	Companies with ANDA and device capabilities
Packaging	High-barrier blister and capsule-packaging suppliers
Lifecycle products	Parkinson's-focused specialty pharmaceutical companies

A licensing transaction could involve formulation know-how, an inhaler platform, regional commercialization rights or a second-source excipient arrangement. The highest-value diligence points are freedom to operate, FDA comparability expectations, device manufacturing capacity and the ability to demonstrate consistent aerodynamic performance at commercial scale.

What revenue exposure is associated with Inbrija?

Inbrija revenue is exposed to five commercial variables:

1. The number of Parkinson's patients with clinically significant off episodes;
2. Prescriber adoption of an inhaled rescue treatment;
3. Reimbursement and specialty-pharmacy access;
4. Patient ability to use the inhaler correctly;
5. Timing and quality of generic or competing rescue-product entry.

The product's per-use economics can be attractive because patients may use multiple capsules per episode. That same dosing pattern increases sensitivity to capsule cost, device reliability, packaging volume and reimbursement restrictions.

Revenue risk is higher if a competitor offers a simpler single-dose rescue product or a device with less patient handling. Revenue protection depends on maintaining reliable delivery, broad payer coverage and a defensible formulation-device patent position.

Key Takeaways

• Inbrija is a carrier-free inhaled levodopa product using DPPC as its principal disclosed excipient.
• DPPC supports pulmonary compatibility and aerosol particle engineering, but pharmaceutical-grade supply qualification is critical.
• The main barriers to competition are particle manufacture, aerodynamic performance, device integration and regulatory comparability.
• Generic entry would likely require an ANDA, Paragraph IV analysis and extensive inhalation-device and aerosol testing.
• The strongest commercial opportunities are inhalation-grade DPPC, custom spray drying, capsule systems, inhaler manufacturing and lifecycle reformulation.
• Levodopa itself provides little composition-of-matter protection because it is an established molecule.
• Patent value is concentrated in formulation, particle, manufacturing, device and method-of-use claims.
• No biosimilar pathway applies because Inbrija is a small-molecule drug, not a biologic.
• Regulatory and commercial exclusivity should be evaluated separately from nominal patent expiration.
• A second-source excipient strategy can reduce supply risk but may require substantial comparability work.

FAQs

Is DPPC the only important excipient in Inbrija?

DPPC is the principal disclosed inactive ingredient in the inhalation powder. Capsule and inhaler materials are also commercially important because they affect moisture protection, powder discharge, dose uniformity and device performance.

Can a generic Inbrija use lactose as a carrier?

A generic could pursue a different excipient architecture, but replacing the carrier-free DPPC particle system with a lactose-based blend could alter emitted dose, aerodynamic distribution, dissolution and lung deposition. The alternative would require product-specific development and regulatory support.

Does Inbrija have biosimilar competition?

No. Inbrija contains levodopa, a small-molecule active ingredient. Competition would proceed through generic or hybrid regulatory pathways rather than the FDA biosimilar pathway.

Could another phospholipid replace DPPC?

Potentially, but the replacement would require evaluation of pulmonary safety, aerosol performance, stability, particle morphology and regulatory comparability. A successful substitute could support a new formulation patent and reduce dependence on DPPC supply.

What is the most defensible commercial position in the Inbrija supply chain?

A qualified inhalation-grade DPPC platform combined with spray-drying know-how and device-specific analytical capability is more defensible than commodity excipient supply alone. The combination creates switching costs and supports regulatory continuity.

References

1. U.S. Food and Drug Administration. (2024). Inbrija (levodopa) inhalation powder: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2018). FDA approves new inhaled formulation of levodopa for Parkinson's disease.
4. U.S. Food and Drug Administration. (2018). Guidance for industry: Metered dose inhaler and dry powder inhaler drug products.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. §355(j).